Cover Image
市場調查報告書

EpiCast Report:類風溼性關節炎──流行病學的預測

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 320340
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:類風溼性關節炎──流行病學的預測 EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023
出版日期: 2014年12月01日 內容資訊: 英文 48 Pages
簡介

類風溼性關節炎(RA)為自體免疫疾病的一種,引起關節發炎。類類風溼性關節炎發病時,人體的免疫系統會攻擊關節內側,產生發炎反應。並且引起在青年時的死亡和身體障礙,生活品質(QoL)降低的問題。全球主要8個國家的類風溼性關節炎的患者數,2013年階段達到12,901,398人,預計2023年達到14,896,291人,其間的年複合成長率(CAGR)估計為1.55%。還有在主要10個國家受診斷的患者數,2013年估計為7,328,399人,預計2023年達到8,518,398人。

本報告提供全球主要國家的類風溼性關節炎(RA)的發病情形與今後預測相關分析、疾病的特徵、及目前患病者的發病情形、今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
    • 澳洲
    • 中國
    • 印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:類風溼性關節炎的患病者總數
    • 預測的前提條件與手法:類風溼性關節炎已診斷的患病人數
  • 類風溼性關節炎的流行病學的預測(今後11年份)
    • 類風溼性關節炎的患病者總數
    • 類風溼性關節炎的患病者總數:各年齡
    • 類風溼性關節炎的患病者總數:男女
    • 類風溼性關節炎已診斷的患病人數
    • 類風溼性關節炎的患病人數(已調整年齡)
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER065-14

Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body's immune system attacks the lining of the joints causing an inflammatory response. RA is characterized by joint swelling, pain, and redness, which can cause bone and cartilage erosion, and joint deformity. The disease can lead to premature mortality, disability, and decreased quality of life.

GlobalData epidemiologists forecast an increase in the total prevalent cases of RA in the 8MM, from 12,901,398 total prevalent cases in 2013 to 14,896,291 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.55% over the forecast period. GlobalData epidemiologists also forecast an increase in the diagnosed prevalent cases of RA in the 10MM, from 7,328,399 diagnosed prevalent cases in 2013 to 8,518,398 diagnosed prevalent cases in 2023, at an AGR of 1.62% over the forecast period.

For this analysis, GlobalData epidemiologists used country-specific data from peer-reviewed journals to construct the 10-year epidemiological forecast for the total prevalent cases of RA in the 8MM. GlobalData epidemiologists built the forecast for the diagnosed prevalent cases of RA in the 10MM using a combination of country-specific primary and secondary sources. A major strength of GlobalData's epidemiological analysis is the use of consistent disease definitions and uniform diagnostic criteria, thereby allowing for a meaningful comparison of the epidemiological characteristics of RA in the 10MM.

Scope

  • The Rheumatoid arthritis (RA) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for RA in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It also includes a 10-year epidemiological forecast for the total prevalent cases of RA, segmented by age (18 to =85 years) and sex in the eight major markets (8MM) (France, Germany, Italy, Spain, UK, Japan, China, and India). Additionally, this report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of RA in the 10MM.
  • The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global RA market.
  • Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RA therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
    • 3.3.4. Australia
    • 3.3.5. China
    • 3.3.6. India
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of RA
    • 3.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA
  • 3.5. Epidemiological Forecast for RA (2013-2023)
    • 3.5.1. Total Prevalent Cases of RA
    • 3.5.2. Age-Specific Total Prevalent Cases of RA
    • 3.5.3. Sex-Specific Total Prevalent Cases of RA
    • 3.5.4. Diagnosed Prevalent Cases of RA
    • 3.5.5. Age-Standardized Diagnosed Prevalence of RA
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 10MM, Sources of RA Prevalence Data
  • Table 4: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 5: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2013
  • Table 6: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2013
  • Table 7: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2013
  • Figure 4: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 5: 10MM, Age-Standardized Prevalence of RA (%), Ages ≥18 Years, 2013
Back to Top